Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04150029 · ClinicalTrials.gov registry record · Phase 2
A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT04150029 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 90 participants.
The verdict
NCT04150029, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
Interventions
- DRUG Venetoclax
- DRUG Azacitidine
- DRUG MBG453
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2020-09-01 |
| Est. Completion | 2024-10-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04150029
The ClinicalTrials.gov registry entry for NCT04150029 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT04150029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04150029 about?
NCT04150029 is a clinical study titled "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy". This trial seeked to extend the preliminary findings of efficacy by evaluating MBG453 in combination with hypomethylating agents (HMA) and also Bcl-2 inhibitor venetoclax.
What is the current status of trial NCT04150029?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2020-09-01. Estimated completion is 2024-10-25.
What interventions are being tested in trial NCT04150029?
The interventions under investigation include: Venetoclax (DRUG), Azacitidine (DRUG), MBG453 (DRUG).
Who is sponsoring clinical trial NCT04150029?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.